On Oct. 7, 2021, Vaxart announced that a Duke University-led study published in bioRxiv showed that Vaxart’s (investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model.

These results are consistent with those from Vaxart’s Phase II human flu challenge study, which showed that Vaxart’s oral tablet vaccine was better at reducing shedding than the injectable flu vaccine comparator.